Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Correction

This article was originally published in The Silver Sheet

Executive Summary

A quote on page 5 of the September 2009 "Silver Sheet" was incorrect. The quote by Jeffrey Secunda, VP for technology and regulatory affairs at device trade association AdvaMed, should have read, "What we would like to see is that the first acknowledgement, which is the most meaningful, will be the actual 'postmark.'" Secunda was speaking about the three-acknowledgement approach to firms used by FDA's electronic Medical Device Reporting (eMDR) program

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT036404

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel